AbbVie v. Derrick Brent: Infringement Suit Over Apoptosis Agent Formulation Dismissed
AbbVie, Inc. brought a patent infringement action against individual defendant Derrick Brent in the Virginia Eastern District Court, asserting US11369599B2 covering melt-extruded solid dispersions containing an apoptosis-inducing agent. The case closed after 218 days when the court granted the defendant’s motions to dismiss and for summary judgment while denying AbbVie’s cross-motion for summary judgment.
AbbVie’s Apoptosis-Agent Patent Claim Ends in Full Dismissal
AbbVie, Inc. filed this patent infringement action on 23 December 2024 in the Virginia Eastern District Court against Derrick Brent, an individual defendant represented by the U.S. Attorney’s Office (DOJ-USAO). The asserted patent, US11369599B2, covers melt-extruded solid dispersions containing an apoptosis-inducing agent — a pharmaceutical formulation technology relevant to targeted cancer therapy products. AbbVie was represented by Bracewell LLP, fielding a five-attorney team.
The case closed on 29 July 2025 — 218 days after filing — when the court issued a Memorandum Opinion granting the defendant’s Motion to Dismiss and Motion for Summary Judgment simultaneously, while denying AbbVie’s own Motion for Summary Judgment. The dual grant of dispositive motions in favor of the defendant, without a trial, suggests the court found either a threshold jurisdictional or standing defect, or that the undisputed facts negated an essential element of AbbVie’s infringement claim as a matter of law.
The involvement of DOJ-USAO as defense counsel is an unusual feature that may indicate the defendant has a governmental or sovereign-adjacent status, which could bear on jurisdiction or immunity. The public record does not disclose the underlying Memorandum Opinion reasoning, the specific grounds for dismissal, or whether AbbVie intends to appeal. The relatively swift resolution — under eight months — is consistent with a case resolved on purely legal rather than factual grounds.
Filing to Case Dismissed in 218 days
218 days — resolved before trial, faster than the median EDVA patent case
Defendant wins on all motions: what the dismissal means for both parties
Simultaneous grant of dismiss and summary judgment signals a decisive legal win
The court granted both a Motion to Dismiss and a Motion for Summary Judgment in the defendant’s favor — and denied AbbVie’s cross-motion for summary judgment. Granting both dispositive vehicles simultaneously is notable: it may reflect redundant pleading by the defense, or that the court identified both a threshold defect and an absence of triable fact. The case is dismissed as a matter of law, with no trial on the merits of infringement.
Decided — defendant prevailsAbbVie’s infringement claim denied at every level of the dispositive briefing
AbbVie’s own Motion for Summary Judgment was denied, and the case was dismissed entirely on the defendant’s motions. This outcome means the asserted patent US11369599B2 did not yield an enforceable judgment in this action. Whether the dismissal is with or without prejudice is not specified in the public termination record. AbbVie’s strategic options — including re-filing, appealing, or pursuing alternative enforcement routes — will depend on the grounds set out in the sealed or unpublished Memorandum Opinion.
Claim extinguished at summary stageDOJ-USAO defense secures full dismissal without trial
Defendant Derrick Brent, defended by the U.S. Attorney’s Office, achieved a complete legal victory: all of AbbVie’s claims were terminated without a trial on infringement. The DOJ-USAO involvement is atypical in patent cases and suggests a potential governmental nexus — possibly sovereign immunity, federal employee status, or governmental use — which may have formed the basis of the successful dismissal argument. The public record does not confirm this, but it is consistent with the outcome.
Full defense victoryPatent US11369599B2 remains unadjudicated on the merits of validity or infringement
Because the case was resolved on procedural or threshold grounds rather than a substantive infringement or validity ruling, US11369599B2’s enforceability against third-party commercial actors is unaffected by this outcome. Competitors developing melt-extruded solid dispersion formulations involving apoptosis-inducing agents should not read this dismissal as a weakening of AbbVie’s patent position. AbbVie retains the patent and may bring future enforcement actions against distinct defendants.
Patent enforcement status unchangedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AbbVie, Inc. | Company | Pharmaceutical innovator — holder of US11369599B2 covering melt-extruded solid dispersionsSearch in Eureka ↗ |
| Defendant | Derrick Brent | Individual | Individual defendant Derrick Brent, represented by DOJ-USAO (U.S. Attorney’s Office)Search in Eureka ↗ |
| Plaintiff counsel | Britt Cass Steckman | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher Lee Crumbley | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Douglas Fred Stewart | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Janelle Luceria Elysee | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Patrick James Connolly | Attorney | Counsel for AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Bracewell LLP | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Bracewell LLP (TX-NA) | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Bracewell LLP (WA-NA) | Law Firm | Representing AbbVie, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew J. Mezger | Attorney | Counsel for Derrick BrentSearch in Eureka ↗ |
| Defendant law firm | DOJ-USAO | Law Firm | Representing Derrick BrentSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Virginia Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The order grants both a Motion to Dismiss and a Motion for Summary Judgment for the defendant while denying AbbVie’s cross-motion — a comprehensive defense victory. The simultaneous use of both dispositive vehicles suggests the defendant may have raised both a threshold justiciability or immunity argument (Motion to Dismiss) and a no-genuine-dispute argument on the merits (Motion for Summary Judgment). The accompanying Memorandum Opinion, not reproduced in the public record, would clarify which ground was dispositive. AbbVie’s denied cross-motion confirms the court found the undisputed facts did not support a plaintiff judgment even on AbbVie’s own framing.
US11369599B2 — Melt-Extruded Solid Dispersions with Apoptosis-Inducing Agent
US11369599B2, filed under application number US14/340435, protects melt-extruded solid dispersion formulations incorporating an apoptosis-inducing agent. Melt extrusion is a pharmaceutical manufacturing process used to enhance the bioavailability of poorly soluble active pharmaceutical ingredients by dispersing them in a polymer matrix. Apoptosis-inducing agents — such as BCL-2 family inhibitors used in oncology — are a therapeutically significant class, and formulation patents of this type can protect a key manufacturing route for commercial drug products.
For AbbVie, formulation patents covering melt-extruded solid dispersions are strategically important because they can extend commercial exclusivity beyond the expiry of composition-of-matter patents on the active ingredient itself. This patent is relevant to any manufacturer developing generic or next-generation oncology products that use melt-extrusion as a processing method with apoptosis-inducing APIs. Companies working in this space — particularly those targeting BCL-2 inhibitor formulations — face meaningful infringement risk if their manufacturing process falls within the claim scope of US11369599B2.
Should your team run an FTO against US11369599B2?
Any pharmaceutical R&D team or contract development and manufacturing organization (CDMO) working on solid dispersion formulations of apoptosis-inducing agents — including BCL-2 inhibitors, BH3 mimetics, or similar oncology APIs — should evaluate freedom-to-operate against US11369599B2. The patent’s melt-extrusion process claims could capture a broad range of manufacturing approaches, and AbbVie’s active enforcement posture makes early FTO analysis a commercial necessity rather than an optional step.
PatSnap Eureka’s FTO Search Agent enables R&D teams to map claim scope against their specific manufacturing process parameters, identify prior art that may limit AbbVie’s claim reach, and surface related continuation or divisional patents in AbbVie’s portfolio that could pose parallel risk. Running an automated FTO on US11369599B2 and its patent family before committing to a melt-extrusion manufacturing pathway can materially reduce freedom-to-operate uncertainty and inform design-around or licensing decisions.
Run a freedom-to-operate analysis on US11369599B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical formulation patent cases in Virginia Eastern District
Explore related patent infringement cases involving pharmaceutical solid dispersion and oncology formulation patents litigated in the Virginia Eastern District Court.
What this case signals for the pharmaceutical formulation IP landscape
AbbVie’s swift defeat on all dispositive motions raises questions about defendant selection, standing, and enforcement strategy for complex pharma patents.
DOJ-USAO defense is a rare signal worth monitoring in pharma patent suits
When the U.S. Attorney’s Office defends an individual in a patent infringement case, it typically suggests federal employment, government contractor status, or a governmental-use defense under 28 U.S.C. § 1498. Patent holders considering enforcement against individuals should screen defendants for governmental nexus before filing, as sovereign immunity and § 1498 can redirect or bar district court claims entirely.
Dismissal without a merits ruling leaves US11369599B2 fully in force
The court’s dismissal appears to rest on threshold grounds rather than a substantive invalidity or non-infringement finding. Pharmaceutical companies working in melt-extruded solid dispersion technology — particularly formulations involving BCL-2 inhibitors or similar apoptosis-inducing agents — should treat AbbVie’s patent as an active enforcement risk and conduct FTO analysis accordingly.
AbbVie v Derrick — key questions answered
The case was dismissed in favor of defendant Derrick Brent. The Virginia Eastern District Court granted the defendant’s Motion to Dismiss and Motion for Summary Judgment, and denied AbbVie’s Motion for Summary Judgment. The case closed on 29 July 2025, approximately 218 days after filing.
AbbVie asserted US11369599B2, filed under application number US14/340435. The patent covers melt-extruded solid dispersions containing an apoptosis-inducing agent — a pharmaceutical formulation technology relevant to oncology drug manufacturing.
The public record does not specify the exact basis for DOJ-USAO representation. However, the U.S. Attorney’s Office typically defends individuals in civil matters when the defendant is a federal employee acting within the scope of their duties, or when a governmental-use defense under 28 U.S.C. § 1498 is available. This is consistent with the successful dismissal outcome, but the Memorandum Opinion’s reasoning is not publicly confirmed.
No. The dismissal appears to rest on threshold or procedural grounds rather than a merits ruling on infringement or validity. US11369599B2 remains in force, and AbbVie retains the right to enforce it against other defendants. The outcome of this case does not constitute a finding that the patent is invalid or not infringed.
A melt-extruded solid dispersion is a pharmaceutical dosage form produced by melting an API together with a polymer carrier to create a single-phase amorphous system, typically improving solubility and bioavailability of poorly water-soluble drugs. Such formulations are patentable when the specific combination of ingredients, process parameters, or resulting structural properties is novel and non-obvious — making them a key tool for extending commercial exclusivity in branded pharmaceutical portfolios.
PatSnap Eureka searches patents and litigation data to answer instantly.